Vitalhub Valuation
Is VHI undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of VHI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: VHI (CA$10.09) is trading below our estimate of fair value (CA$34.31)
Significantly Below Fair Value: VHI is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for VHI?
Key metric: As VHI is barely profitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is VHI's PS Ratio? | |
|---|---|
| PS Ratio | 8.6x |
| Sales | CA$61.61m |
| Market Cap | CA$529.55m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 7.3x |
| Enterprise Value/EBITDA | 34.7x |
| PEG Ratio | 1.5x |
Price to Sales Ratio vs Peers
How does VHI's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 5.4x | ||
KSI kneat.com | 10.5x | 28.5% | CA$473.7m |
RHT Reliq Health Technologies | 3.2x | n/a | CA$47.3m |
NURS Hydreight Technologies | 1.8x | n/a | CA$25.4m |
CDX.H Cloud DX | 6.2x | n/a | CA$12.1m |
VHI Vitalhub | 8.6x | 19.4% | CA$529.5m |
Price-To-Sales vs Peers: VHI is expensive based on its Price-To-Sales Ratio (8.6x) compared to the peer average (5.4x).
Price to Sales Ratio vs Industry
How does VHI's PS Ratio compare vs other companies in the CA Healthcare Services Industry?
Price-To-Sales vs Industry: VHI is expensive based on its Price-To-Sales Ratio (8.6x) compared to the North American Healthcare Services industry average (2.1x).
Price to Sales Ratio vs Fair Ratio
What is VHI's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 8.6x |
| Fair PS Ratio | 7x |
Price-To-Sales vs Fair Ratio: VHI is expensive based on its Price-To-Sales Ratio (8.6x) compared to the estimated Fair Price-To-Sales Ratio (7x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | CA$10.09 | CA$13.33 +32.1% | 9.4% | CA$15.00 | CA$12.00 | n/a | 6 |
| Nov ’25 | CA$10.25 | CA$10.96 +6.9% | 9.9% | CA$13.00 | CA$10.00 | n/a | 6 |
| Oct ’25 | CA$8.50 | CA$9.83 +15.7% | 4.8% | CA$10.50 | CA$9.00 | n/a | 6 |
| Sep ’25 | CA$8.02 | CA$9.67 +20.5% | 3.9% | CA$10.00 | CA$9.00 | n/a | 6 |
| Aug ’25 | CA$8.10 | CA$8.25 +1.9% | 5.8% | CA$8.75 | CA$7.50 | n/a | 6 |
| Jul ’25 | CA$7.42 | CA$8.08 +8.9% | 5.3% | CA$8.75 | CA$7.50 | n/a | 6 |
| Jun ’25 | CA$6.88 | CA$7.88 +14.5% | 4.4% | CA$8.50 | CA$7.50 | n/a | 6 |
| May ’25 | CA$6.37 | CA$7.71 +21.0% | 4.7% | CA$8.50 | CA$7.50 | n/a | 6 |
| Apr ’25 | CA$6.00 | CA$7.54 +25.7% | 7.8% | CA$8.50 | CA$6.75 | n/a | 6 |
| Mar ’25 | CA$5.77 | CA$6.38 +10.5% | 8.1% | CA$7.00 | CA$5.50 | n/a | 6 |
| Feb ’25 | CA$4.55 | CA$5.46 +20.0% | 10.0% | CA$6.00 | CA$4.50 | n/a | 6 |
| Jan ’25 | CA$4.08 | CA$5.46 +33.8% | 10.0% | CA$6.00 | CA$4.50 | n/a | 6 |
| Dec ’24 | CA$4.31 | CA$5.33 +23.7% | 10.4% | CA$6.00 | CA$4.50 | n/a | 6 |
| Nov ’24 | CA$2.85 | CA$5.13 +79.8% | 10.4% | CA$6.00 | CA$4.25 | CA$10.25 | 6 |
| Oct ’24 | CA$2.95 | CA$5.13 +73.7% | 10.4% | CA$6.00 | CA$4.25 | CA$8.50 | 6 |
| Sep ’24 | CA$2.77 | CA$5.13 +85.0% | 10.4% | CA$6.00 | CA$4.25 | CA$8.02 | 6 |
| Aug ’24 | CA$2.49 | CA$4.92 +97.5% | 11.2% | CA$6.00 | CA$4.25 | CA$8.10 | 6 |
| Jul ’24 | CA$2.56 | CA$4.92 +92.1% | 11.2% | CA$6.00 | CA$4.25 | CA$7.42 | 6 |
| Jun ’24 | CA$2.70 | CA$4.92 +82.1% | 11.2% | CA$6.00 | CA$4.25 | CA$6.88 | 6 |
| May ’24 | CA$2.68 | CA$4.92 +83.5% | 11.2% | CA$6.00 | CA$4.25 | CA$6.37 | 6 |
| Apr ’24 | CA$2.54 | CA$4.92 +93.6% | 11.2% | CA$6.00 | CA$4.25 | CA$6.00 | 6 |
| Mar ’24 | CA$2.63 | CA$4.96 +88.5% | 11.1% | CA$6.00 | CA$4.25 | CA$5.77 | 6 |
| Feb ’24 | CA$2.88 | CA$4.96 +72.2% | 11.1% | CA$6.00 | CA$4.25 | CA$4.55 | 6 |
| Jan ’24 | CA$2.65 | CA$4.96 +87.1% | 11.1% | CA$6.00 | CA$4.25 | CA$4.08 | 6 |
| Dec ’23 | CA$2.26 | CA$4.75 +110.2% | 6.7% | CA$5.00 | CA$4.25 | CA$4.31 | 5 |
| Nov ’23 | CA$2.32 | CA$4.80 +106.9% | 7.7% | CA$5.25 | CA$4.25 | CA$2.85 | 5 |
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.
Discover undervalued companies
NeuPath Health
CA$9.0m
Provides chronic pain management services in Canada.
NPTH
CA$0.16
7D
0%
1Y
3.2%
Medical Facilities
CA$369.6m
Through its subsidiaries, owns and operates specialty hospitals and ambulatory surgery center in the United States.
DR
CA$15.73
7D
4.4%
1Y
81.2%
Carebook Technologies
CA$6.2m
Engages in the development and commercialization of digital health platforms for assessments, reporting, and targeted solutions in Canada, the United States, Europe, Latin America, Asia, and internationally.
CRBK
CA$0.06
7D
-25.0%
1Y
-14.3%